
The role of mid‐treatment monitoring dual‐energy X‐ray absorptiometry–bone mineral density (DXA‐BMD) for bisphosphonate‐treated patients with osteoporosis remains unsettled. A common reason for such monitoring is to encourage ongoing medication adherence. We sought to determine if a DXA‐BMD treatment monitoring test was associated with improved medication adherence and whether improved adherence after a DXA‐BMD treatment monitoring test was associated with subsequent reduction in fracture rates...
Like
Save
Share